Neurodegenerative disease management最新文献

Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study. donanemab和lecanemab使用者在现实环境中的基线流行病学差异：一项回顾性队列研究。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-05-07 DOI: 10.1080/17582024.2026.2667432

Filipi Fim Andreão, Rebeca Oliveira da Silva, Maria Fernanda Liphaus Almeida Negreli, Ana Beatriz P Aguiar-Barros, Diogo Haddad Santos

{"title":"Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study.","authors":"Filipi Fim Andreão, Rebeca Oliveira da Silva, Maria Fernanda Liphaus Almeida Negreli, Ana Beatriz P Aguiar-Barros, Diogo Haddad Santos","doi":"10.1080/17582024.2026.2667432","DOIUrl":"https://doi.org/10.1080/17582024.2026.2667432","url":null,"abstract":"Aims: Donanemab and Lecanemab are anti-amyloid monoclonal antibodies recently approved for the treatment of Alzheimer's disease. Although their efficacy and safety have been investigated in randomized trials, real-world epidemiological data on treated populations remain limited. This study aimed to compare baseline clinical and laboratory characteristics of patients treated with donanemab versus lecanemab in routine practice.Patients and methods: We conducted a retrospective analysis using the TriNetX US Collaborative Network, including patients with Alzheimer's disease treated with donanemab or lecanemab between January 2024 and September 2025. Demographics, laboratory values, comorbidities, and concomitant medications were compared using standardized mean differences (SMD) and p-values. Variables with SMD ≥0.1 or p < 0.05 were considered meaningfully different.Results: A total of 1,799 patients were included (donanemab n = 360; lecanemab n = 1,439). Demographic characteristics were well balanced (mean age 73.1 vs 72.5 years; SMD 0.028). Lecanemab users were more likely to be prescribed antidepressants (52% vs 41%; p < 0.0001; SMD = 0.23) and donepezil (61% vs 52%; p = 0.0145; SMD = 0.14). Donanemab users had higher prothrombin time (12.2 ± 2.17 vs 11.8 ± 1.66 s; p = 0.0158; SMD = 0.20) and INR (1.06 ± 0.19 vs 1.03 ± 0.13; p = 0.0369; SMD = 0.17), and a higher prevalence of vascular dementia (81% vs 76%; p = 0.0272; SMD = 0.12).Conclusion: While demographic variables were similar. These findings likely reflect real-world clinical selection patterns and should be accounted for in comparative effectiveness and safety analyses of anti-amyloid therapies.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-6"},"PeriodicalIF":3.4,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting excitatory/inhibitory neurotransmission by wogonin: integrated In Silico and In Vivo evidence in Parkinson's disease model. wogonin靶向兴奋性/抑制性神经传递：帕金森病模型的综合计算机和体内证据

IF 3.4

Neurodegenerative disease management Pub Date : 2026-05-07 DOI: 10.1080/17582024.2026.2669596

Shivani Chib, Bhaskar Jyoti Dutta, Randhir Singh

{"title":"Targeting excitatory/inhibitory neurotransmission by wogonin: integrated In Silico and In Vivo evidence in Parkinson's disease model.","authors":"Shivani Chib, Bhaskar Jyoti Dutta, Randhir Singh","doi":"10.1080/17582024.2026.2669596","DOIUrl":"https://doi.org/10.1080/17582024.2026.2669596","url":null,"abstract":"Aim: The present study aimed to investigate neuroprotective potential of wogonin in rotenone-induced PD, with particular focus on modulation of excitatory/inhibitory (E/I) neurotransmission and other pathological factors, including oxidative stress, neuroinflammation, and apoptosis.Methods: In-silico molecular docking and molecular dynamics simulation (MDS) were employed to assess binding affinity and stability of wogonin. Wistar rats were divided into six groups (n = 8) and treated with vehicle (1% DMSO), rotenone (2 mg/kg), wogonin (5, 10, and 20 mg/kg), and standard treatment for 21 days. Behavioral assessments were conducted weekly. On day 22, brain tissues were collected for analysis. Oxidative stress markers (MDA, GSH, and LDH) and Ca2+ levels were measured using chemical assays. IL-6, caspase-3/9, parvalbumin, and c-FOS were quantified by ELISA and dopamine levels by HPLC-ECD. Western blotting was performed for GABA-A, gephyrin, MAO-B, and α-synuclein, while tyrosine hydroxylase (TH) expression and neuronal integrity were evaluated histologically.Results: Docking and MDS suggested stable drug-target interactions. Rotenone-induced motor deficits, elevated MDA, LDH, IL-6, caspase-3/9, Ca2+, and c-FOS level and reduced GSH, dopamine, gephyrin, GABA-A, and TH expression. Wogonin dose-dependently attenuated these changes and preserved striatal histoarchitecture.Conclusion: Wogonin modulated the markers related to E/I neurotransmission and exhibited neuroprotection, highlighting its multitarget therapeutic potential in PD.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-15"},"PeriodicalIF":3.4,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 3.4

Neurodegenerative disease management Pub Date : 2026-05-06 DOI: 10.1080/17582024.2026.2669595

J S Sevitz, J A Curtis, N Vanegas-Arroyave, M S Troche

{"title":"Swallowing-related quality of life in progressive supranuclear palsy.","authors":"J S Sevitz, J A Curtis, N Vanegas-Arroyave, M S Troche","doi":"10.1080/17582024.2026.2669595","DOIUrl":"https://doi.org/10.1080/17582024.2026.2669595","url":null,"abstract":"Aims: Dysphagia in Progressive Supranuclear Palsy (PSP) has devastating consequences, including pneumonia and death; however, no studies have described its impact on quality of life (QOL), limiting the degree to which management approaches align with patient needs. Therefore, in this cross-sectional retrospective analysis we characterized swallowing-related QOL (SWAL-QOL) in PSP and assessed its relationship with demographic and clinical characteristics.Patients & methods: Consecutive outpatients completed an assessment of swallowing including the SWAL-QOL questionnaire. Correlations and Wilcoxon sum-rank tests were used to examine whether SWAL-QOL total score (primary analysis) and domain scores (exploratory analysis) differed by demographic variables (age, sex, disease duration), diet status, cognition (MoCA), and swallowing safety.Results: Thirty-five patients with PSP were included (mean age 71, 14F). Median SWAL-QOL total score was 72.1 [IQR 52.6, 82.8]. The most impaired domains were eating duration, fatigue, and communication (M = 50). Those on modified diets had significantly lower total scores (M = 44.1) than those on regular diets (M = 79.8) (W = 22; p = .003). No relationship between total score and age (ρ = 0.30; p = .079), sex (W = 126; p = 0.495), disease duration (ρ = -0.161; p = .354), cognition (ρ=0.207; p = .273), or swallowing safety (χ2 = 1.89; p = .389) was found.Conclusions: SWAL-QOL is reduced in PSP and findings suggest that attention to eating duration and diet modification may inform person-centered care.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-6"},"PeriodicalIF":3.4,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between grip strength, functional outcome, and health-related quality of life measurements in amyotrophic lateral sclerosis patients. 肌萎缩性侧索硬化症患者握力、功能结局和健康相关生活质量测量的关系

IF 3.4

Neurodegenerative disease management Pub Date : 2026-05-05 DOI: 10.1080/17582024.2026.2667425

Xiaolu Liu, Dilip Dhakal, Sixin Gu, Guantong Li, Mei Jing, Gaoxiao Zhang, Yuqiang Wang, Zaijun Zhang, Dongsheng Fan

{"title":"Relationship between grip strength, functional outcome, and health-related quality of life measurements in amyotrophic lateral sclerosis patients.","authors":"Xiaolu Liu, Dilip Dhakal, Sixin Gu, Guantong Li, Mei Jing, Gaoxiao Zhang, Yuqiang Wang, Zaijun Zhang, Dongsheng Fan","doi":"10.1080/17582024.2026.2667425","DOIUrl":"https://doi.org/10.1080/17582024.2026.2667425","url":null,"abstract":"Aim: To explore how grip strength is related to functional status and health-related quality of life (HRQoL) in amyotrophic lateral sclerosis (ALS) patients.Methods: In the phase 2 trial of TBN for treatment of ALS, 148 patients in full analysis set received TBN (600 mg or 1200 mg) or a placebo for 180 days. Outcome measurements included ALS Functional Rating Scale-Revised (ALSFRS-R), 40-item ALS Assessment Questionnaire (ALSAQ-40), grip strength, and forced vital capacity (FVC). Spearman's rank correlation was used to examine associations between grip strength, ALSFRS-R and ALSAQ-40. A principal component analysis-ANCOVA model adjusted for sex was used to further explore the associations.Results: Grip strength was strongly correlated with ALSFRS-R fine motor function domain (rs = 0.740) and moderately correlated with ALSAQ-40 activities of daily living (ADL) domain (rs = -0.637) (p < 0.05). Weak correlations were observed between FVC and both ALSFRS-R total score (rs = 0.355) and respiratory domain (rs = 0.229) and ALSAQ-40 domains. Grip strength was a strong predictor of ALSFRS-R fine motor and ALSAQ-40 ADL domains.Conclusion: Grip strength was associated with functional status and HRQoL, supporting its potential role as a meaningful clinical outcome measure in patients with ALS.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":3.4,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of spinocerebellar ataxia. 脊髓小脑共济失调的治疗。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-30 DOI: 10.1080/17582024.2026.2665356

Egor Vinokurov, Ksenia Marinina, Ilya Bezprozvanny

{"title":"Management of spinocerebellar ataxia.","authors":"Egor Vinokurov, Ksenia Marinina, Ilya Bezprozvanny","doi":"10.1080/17582024.2026.2665356","DOIUrl":"https://doi.org/10.1080/17582024.2026.2665356","url":null,"abstract":"Spinocerebellar ataxias (SCAs) are a group of neurodegenerative diseases characterized by progressive cerebellar dysfunction, which leads to impaired coordination, dysarthria, oculomotor disorders, and subsequently to a marked reduction in quality of life and high disability. In addition to the main motor symptoms, patients often suffer from cerebellar cognitive-affective syndrome, depression, and sleep disturbances. Despite advances in understanding the molecular and genetic underpinnings of SCAs, there are currently no disease-modifying therapies approved by the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency), and management remains largely symptomatic, focusing on improving quality of life and functional independence. Recent systematic reviews and clinical guidelines emphasize a combination of pharmacological, non-pharmacological, and novel gene and cell therapies that are currently under investigation, with varying levels of evidence for their efficacy. The transition to precision medicine and early intervention at the pre-ataxic stage are essential for effectively combating neurodegeneration. This review summarizes the latest data on the treatment of SCA, including existing and new treatments, their effectiveness, limitations, and future prospects.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-19"},"PeriodicalIF":3.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pilates as therapy for multiple sclerosis: current perspective and future directions. 普拉提作为多发性硬化症的治疗：目前的观点和未来的方向。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-30 DOI: 10.1080/17582024.2026.2664405

Parisa Najafi, Louise Declerck, Robert Motl

{"title":"Pilates as therapy for multiple sclerosis: current perspective and future directions.","authors":"Parisa Najafi, Louise Declerck, Robert Motl","doi":"10.1080/17582024.2026.2664405","DOIUrl":"https://doi.org/10.1080/17582024.2026.2664405","url":null,"abstract":"Multiple sclerosis (MS) is a disease of the central nervous system (CNS) that often results in walking and balance impairments, fatigue, depression, and reduced quality of life (QOL). Exercise is beneficial for people with MS, and mind-body approaches like Pilates offer unique benefits, perhaps through activity-dependent neuroplasticity. The paper provides an overview of Pilates exercise as therapy in MS, and presents evidence from RCTs supporting its benefits, safety, and application in MS. We located 31 RCTs examining Pilates interventions in MS. There was consistent evidence for improvements in fatigue, balance, QOL, walking performance, mood, and select biochemical markers. However, the generalizability of the RCT evidence is limited by the predominance of studies from a single geographic region and mainly samples of young and middle-aged adults with MS, variability in intervention protocols, underrepresentation of important outcomes such as motor-cognitive function, and inconsistent reporting of adherence and safety. Overall, Pilates represents a holistic, evidence-informed approach with considerable potential for improving outcomes in people with MS, and we offer recommendations for future research on Pilates in MS.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuro-reparative potential of hyperbaric oxygen therapy in animal models of Alzheimer's and Parkinson's diseases: systematic review and meta-analysis. 高压氧治疗在阿尔茨海默病和帕金森病动物模型中的神经修复潜力：系统回顾和荟萃分析

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-30 DOI: 10.1080/17582024.2026.2665357

Aiswarya Radhakrishnan, Debprasad Dutta, Moupali Saha, Srikant Venkatakrishnan, Akshay Kulkarni, Komal Prasad Chandrachari, Paul C Salins, Amritha Suresh

{"title":"Neuro-reparative potential of hyperbaric oxygen therapy in animal models of Alzheimer's and Parkinson's diseases: systematic review and meta-analysis.","authors":"Aiswarya Radhakrishnan, Debprasad Dutta, Moupali Saha, Srikant Venkatakrishnan, Akshay Kulkarni, Komal Prasad Chandrachari, Paul C Salins, Amritha Suresh","doi":"10.1080/17582024.2026.2665357","DOIUrl":"https://doi.org/10.1080/17582024.2026.2665357","url":null,"abstract":"Introduction: This systematic review and meta-analysis explored the efficacy of Hyperbaric oxygen therapy (HBOT) in preclinical models of Alzheimer's disease (AD) and Parkinson's disease (PD).Methods: Data were extracted as per PRISMA guidelines using specific search criteria, with bias assessed using SYRCLE guidelines. Random-effect models were used for meta-analyses of key outcomes, and forest plots were generated. Outcomes assessed included cognitive and motor performance, neuroinflammation, oxidative stress, mitochondrial function, apoptosis, and dopaminergic neuron survival.Results: The PRISMA search yielded 8 studies (AD: 3; PD: 5) from a total of 8261 articles identified. A total of 308 animals were reported across the studies; however, 182 were included in the meta-analysis, as only animals from relevant treatment and corresponding control groups with extractable outcome data were eligible for quantitative analysis. HBOT significantly improved cognitive function (reduced escape latency, Standardized Mean Difference; SMD: -2.13), improved spatial memory, and reduced compensatory locomotor activity (decreased distance traveled, SMD: -6.94). The markers of neuroinflammation (lower TNF-α, higher IL-10), oxidative stress (SOD, MDA), mitochondrial biogenesis (SIRT1, PGC-1α, TFAM, VDAC), and anti-apoptotic markers (higher Bcl-xl, lower Bax) showed differences in post-HBO treatment. HBOT also preserved dopaminergic neurons in PD models.Conclusions: These preclinical findings support HBOT as a potential complementary neuroprotective therapy for AD and PD, warranting further clinical validation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical correlates of global and axial levodopa response in Parkinson's disease. 帕金森病左旋多巴整体和轴向反应的临床相关性

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-28 DOI: 10.1080/17582024.2026.2664406

Halil Onder, Meral Oksuz, Ismet Melek, Selcuk Comoglu

{"title":"Clinical correlates of global and axial levodopa response in Parkinson's disease.","authors":"Halil Onder, Meral Oksuz, Ismet Melek, Selcuk Comoglu","doi":"10.1080/17582024.2026.2664406","DOIUrl":"https://doi.org/10.1080/17582024.2026.2664406","url":null,"abstract":"Background: Levodopa response (LDR) is central to the clinical assessment of Parkinson's disease (PD), yet the factors influencing axial motor responsiveness remain insufficiently explored.Objective: To identify clinical determinants of overall LDR and the levodopa response of axial symptoms (LDR-axial).Methods: Consecutive PD patients evaluated between January and August 2024 were included. MDS-UPDRS-3 was administered in defined \"off\" and suprathreshold \"on\" states. LDR and LDR-axial were calculated as proportional score changes. Motor, non-motor, and cognitive variables were analyzed using multiple regression models.Results: Forty-five patients (mean age 61.9 ± 8.6 years) were enrolled. The mean LDR was 0.36 ± 0.14, and the median LDR-axial was 0.27. Group comparisons did not reveal significant differences. In regression analyses, the Non-Motor Symptoms Scale (NMSS) was the only independent predictor of overall LDR (β = -0.407). For LDR-axial, semantic fluency emerged as the sole significant predictor (β = 0.332), and patients with limited axial improvement had significantly lower semantic fluency scores.Conclusions: Higher non-motor symptom burden is associated with reduced dopaminergic motor responsiveness. Semantic fluency correlates with LDR-axial, suggesting a potential cognitive marker linked to nondopaminergic mechanisms underlying axial symptom resistance. These findings warrant further investigation in larger cohorts.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":3.4,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rising dementia mortality among tobacco users in the US, 2005-2020: insights from CDC-WONDER database. 2005-2020年美国烟草使用者痴呆症死亡率上升：来自CDC-WONDER数据库的见解

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-14 DOI: 10.1080/17582024.2026.2647102

Maryam Saghir, Muhammad Affan, Eshal Saghir, Khola Qazi, Mahtab Zafar, Sima Rawal, Nara Michaelson, Yasar Sattar

{"title":"Rising dementia mortality among tobacco users in the US, 2005-2020: insights from CDC-WONDER database.","authors":"Maryam Saghir, Muhammad Affan, Eshal Saghir, Khola Qazi, Mahtab Zafar, Sima Rawal, Nara Michaelson, Yasar Sattar","doi":"10.1080/17582024.2026.2647102","DOIUrl":"https://doi.org/10.1080/17582024.2026.2647102","url":null,"abstract":"Background: Dementia is a leading cause of morbidity and mortality in the aging population, with tobacco use recognized as a major modifiable risk factor. Despite this established link, national trends in mortality due to dementia among tobacco users remain underexplored.Methods: We analyzed deaths due to dementia in tobacco users using the CDC WONDER database from 2005 to 2020. Age-adjusted mortality rates per 100,000 of the US population were calculated and categorized by demographics and region. Joinpoint regression was used to estimate Annual Percent Change and Average Annual Percent Change.Results: A total of 63,623 deaths due to dementia among tobacco users were recorded among older adults aged ≥65 years. The AAMR observed a significantly steep incline from 3.25 in 2005 to 12.87 in 2020. Men observed higher overall AAMR than women. Non-Hispanic White population had the highest overall AAMR. Regionally, the highest AAMR was recorded in the Midwest and non-metropolitan areas.Conclusion: Deaths due to dementia among tobacco users has risen sharply in the U.S. with marked disparities by sex, race, and geography. These findings highlight the urgent need for targeted smoking cessation programs and equitable dementia care strategies to mitigate the growing burden.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study. 关于克拉德宾在复发性多发性硬化症中的临床和机制作用的简单语言总结：来自MAGNIFY-MS研究的2年结果。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-06 DOI: 10.1080/17582024.2026.2646302

Klaus Schmierer, Heinz Wiendl, Frederik Barkhof, Xavier Montalban, Anat Achiron, Tobias Derfuss, Andrew Chan, Suzanne Hodgkinson, Alexandre Prat, Letizia Leocani, Finn Sellebjerg, Patrick Vermersch, Hulin Jin, Laura Sponton, Anita Chudecka, Meg Bucello, Lidia Gardner, Nicola De Stefano

引用次数: 0